The prognosis of patients diagnosed with advanced ovarian or endometrial cancer remains poor, and effective therapeutic strategies are limited. The Müllerian inhibiting substance type 2 receptor (MISIIR) is a transforming growth factor β (TGF-β) receptor family member, overexpressed by most ovarian and endometrial cancers while absent in most normal tissues. Restricted tissue expression, coupled with an understanding that MISIIR ligation transmits apoptotic signals to cancer cells, makes MISIIR an attractive target for tumor-directed therapeutics. However, the development of clinical MISIIR-targeted agents has been challenging. Prompted by the responses achieved in patients with blood malignancies using chimeric antigen receptor (CAR) T cell therapy, we hypothesized that MISIIR targeting may be achieved using a CAR T cell approach. Herein, we describe the development and evaluation of a CAR that targets MISIIR. T cells expressing the MISIIR-specific CAR demonstrated antigen-specific reactivity in vitro and eliminated MISIIR-overexpressing tumors in vivo. MISIIR CAR T cells also recognized a panel of human ovarian and endometrial cancer cell lines, and they lysed a battery of patient-derived tumor specimens in vitro, without mediating cytotoxicity of a panel of normal primary human cells. In conclusion, these results indicate that MISIIR targeting for the treatment of ovarian cancer and other gynecologic malignancies is achievable using CAR technology.
Keywords: AMHR2; CAR T cell therapy; MISIIR; MISR2; MISRII; chimeric antigen receptor; immunotherapy; mullerian inhibiting substance type 2 receptor; ovarian cancer.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.
Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.Gynecol Oncol. 2008 Jan;108(1):141-8. doi: 10.1016/j.ygyno.2007.09.010. Epub 2007 Nov 7. Gynecol Oncol. 2008. PMID: 17988723
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer.Mol Cancer Ther. 2006 Aug;5(8):2096-105. doi: 10.1158/1535-7163.MCT-06-0115. Mol Cancer Ther. 2006. PMID: 16928831
An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.J Vis Exp. 2010 Nov 28;(45):2146. doi: 10.3791/2146. J Vis Exp. 2010. PMID: 21178956 Free PMC article.
[Mullerian inhibiting substance type II receptor as a potential target for antineoplastic therapy].Biomed Khim. 2019 Apr;65(3):202-213. doi: 10.18097/PBMC20196503202. Biomed Khim. 2019. PMID: 31258143 Review. Russian.
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29861325 Review.
Cited by 1 article
Long non-coding RNA HAL suppresses the migration and invasion of serous ovarian cancer by inhibiting EMT signaling pathway.Biosci Rep. 2020 Mar 27;40(3):BSR20194496. doi: 10.1042/BSR20194496. Biosci Rep. 2020. PMID: 32039453 Free PMC article.